medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2021, Número S3

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2021; 32 (S3)


Tratamiento actual más allá de las estatinas en la hipercolesterolemia: cuanto más bajo mejor en la prevención de las enfermedades ateroscleróticas

Gómez-Álvarez EB, Alcocer-Chauvet A, Hernández-Flores KR

Idioma: Inglés [English version]
Referencias bibliográficas: 15
Paginas: s217-224
Archivo PDF: 361.77 Kb.





REFERENCIAS (EN ESTE ARTÍCULO)

  1. Choi JY, Na JO. Pharmacological strategies beyond statins: ezetimibe and PCSK9 inhibitors. J Lipid Atheroscler. 2019; 8 (2): 183-191.

  2. Landmesser U, Chapman MJ, Stock JK, Amarenco P, Belch JJF, Borén J et al. 2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. Eur Heart J. 2018; 39 (14): 1131-1143.

  3. Ray KK, Corral P, Morales E, Nicholls SJ. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019; 394 (10199): 697-708.

  4. Ma YB, Chan P, Zhang Y, Tomlinson B, Liu Z. Evaluating the efficacy and safety of atorvastatin + ezetimibe in a fixed-dose combination for the treatment of hypercholesterolemia. Expert Opin Pharmacother. 2019; 20 (8): 917-928.

  5. Agarwala A, Kajani Z, Miedema MD, Virani SS. The role of ezetimibe in the treatment of cardiovascular disease. Curr Atheroscler Rep [Internet]. 2016; 18 (2). Available in: http://dx.doi.org/10.1007/s11883-016-0560-y

  6. Al Badarin FJ, Kullo IJ, Kopecky SL, Thomas RJ. Impact of ezetimibe on atherosclerosis: Is the jury still out? Mayo Clin Proc. 2009; 84 (4): 353-361.

  7. Correction to: Use of risk assessment tools to guide decision-making in the primary prevention of atherosclerotic cardiovascular disease: a special report from the American Heart Association and American College of Cardiology. J Am Coll Cardiol. 2019; 73 (24): 3234-3237.

  8. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41 (1): 111-188.

  9. Rosenson RS, Hegele RA, Fazio S, Cannon CP. The evolving future of PCSK9 inhibitors. J Am Coll Cardiol. 2018; 72 (3): 314-329.

  10. Stoekenbroek RM, Kastelein JJP, Huijgen R. PCSK9 inhibition: the way forward in the treatment of dyslipidemia. BMC Med. 2015; 13 (1): 258.

  11. Ogura M. PCSK9 inhibition in the management of familial hypercholesterolemia. J Cardiol. 2018; 71 (1): 1-7.

  12. Steffens D, Bramlage P, Scheeff C, Kasner M, Hassanein A, Friebel J et al. PCSK9 inhibitors and cardiovascular outcomes. Expert Opin Biol Ther. 2020; 20 (1): 35-47.

  13. Sabatine MS, Giugliano RP, Wiviott SD. for the open-label study of long-term evaluation against ldl cholesterol (OSLER) investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1500-1509.

  14. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019; 73 (24): e285-e350.

  15. Dixon DL, Pamulapati LG, Bucheit JD, Sisson EM, Smith SR, Kim CJ et al. Recent updates on the use of PCSK9 inhibitors in patients with atherosclerotic cardiovascular disease. Curr Atheroscler Rep. 2019; 21 (5): 16.




2020     |     www.medigraphic.com